280 related articles for article (PubMed ID: 30562096)
1. Pulmonary Production of Soluble ST2 in Heart Failure.
Pascual-Figal DA; Pérez-Martínez MT; Asensio-Lopez MC; Sanchez-Más J; García-García ME; Martinez CM; Lencina M; Jara R; Januzzi JL; Lax A
Circ Heart Fail; 2018 Dec; 11(12):e005488. PubMed ID: 30562096
[TBL] [Abstract][Full Text] [Related]
2. The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myocardium.
Tseng CCS; Huibers MMH; van Kuik J; de Weger RA; Vink A; de Jonge N
J Cardiovasc Transl Res; 2018 Feb; 11(1):15-21. PubMed ID: 29285671
[TBL] [Abstract][Full Text] [Related]
3. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans.
Pusceddu I; Dieplinger B; Mueller T
Clin Chim Acta; 2019 Aug; 495():493-500. PubMed ID: 31136737
[TBL] [Abstract][Full Text] [Related]
4. Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress.
Veeraveedu PT; Sanada S; Okuda K; Fu HY; Matsuzaki T; Araki R; Yamato M; Yasuda K; Sakata Y; Yoshimoto T; Minamino T
Biochem Pharmacol; 2017 Aug; 138():73-80. PubMed ID: 28450225
[TBL] [Abstract][Full Text] [Related]
5. Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model.
Takenaga K; Akimoto M; Koshikawa N; Nagase H
PLoS One; 2020; 15(4):e0232230. PubMed ID: 32340025
[TBL] [Abstract][Full Text] [Related]
6. Effects of obesity on IL-33/ST2 system in heart, adipose tissue and liver: study in the experimental model of Zucker rats.
Ragusa R; Cabiati M; Guzzardi MA; D'Amico A; Giannessi D; Del Ry S; Caselli C
Exp Mol Pathol; 2017 Apr; 102(2):354-359. PubMed ID: 28274612
[TBL] [Abstract][Full Text] [Related]
7. ST2 Signaling in the Tumor Microenvironment.
Chang CP; Hu MH; Hsiao YP; Wang YC
Adv Exp Med Biol; 2020; 1240():83-93. PubMed ID: 32060890
[TBL] [Abstract][Full Text] [Related]
8. A role for soluble ST2 in vascular remodeling associated with obesity in rats.
Martínez-Martínez E; Miana M; Jurado-López R; Rousseau E; Rossignol P; Zannad F; Cachofeiro V; López-Andrés N
PLoS One; 2013; 8(11):e79176. PubMed ID: 24265755
[TBL] [Abstract][Full Text] [Related]
9. Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers.
Sánchez-Más J; Lax A; Asensio-López Mdel C; Fernandez-Del Palacio MJ; Caballero L; Santarelli G; Januzzi JL; Pascual-Figal DA
Eur J Clin Invest; 2014 Jul; 44(7):643-51. PubMed ID: 24837094
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-33 and Soluble ST2 Levels in Infants with Hypoxic-Ischemic Encephalopathy.
Hamano H; Takahashi K; Kimura S; Matsuguma C; Kaneyasu H; Fujimoto Y; Ohta N; Okada S; Hasegawa S
Neonatology; 2023; 120(3):353-362. PubMed ID: 36996771
[TBL] [Abstract][Full Text] [Related]
11. Soluble ST2: A complex and diverse role in several diseases.
Homsak E; Gruson D
Clin Chim Acta; 2020 Aug; 507():75-87. PubMed ID: 32305537
[TBL] [Abstract][Full Text] [Related]
12. Alteration of the IL-33-sST2 pathway in hypertensive patients and a mouse model.
Yin X; Cao H; Wei Y; Li HH
Hypertens Res; 2019 Nov; 42(11):1664-1671. PubMed ID: 31235844
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of ST2 in patients with chronic heart failure of ischemic etiology and carbohydrate metabolism disorders.
Grakova EV; Kopeva KV; Teplyakov AT; Ogurkova ON; Garganeeva AA; Garmaeva OV
Ter Arkh; 2019 Mar; 91(1):32-37. PubMed ID: 31090368
[TBL] [Abstract][Full Text] [Related]
14. Soluble ST2 suppresses IL-5 production by human basophilic KU812 cells, induced by epithelial cell-derived IL-33.
Matsumoto K; Kouzaki H; Kikuoka H; Kato T; Tojima I; Shimizu S; Shimizu T
Allergol Int; 2018 Sep; 67S():S32-S37. PubMed ID: 29941231
[TBL] [Abstract][Full Text] [Related]
15. Soluble ST2 in end-stage heart failure, before and after support with a left ventricular assist device.
Tseng CCS; Huibers MMH; Gaykema LH; Siera-de Koning E; Ramjankhan FZ; Maisel AS; de Jonge N
Eur J Clin Invest; 2018 Mar; 48(3):. PubMed ID: 29325227
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective.
Jenkins WS; Roger VL; Jaffe AS; Weston SA; AbouEzzeddine OF; Jiang R; Manemann SM; Enriquez-Sarano M
Am J Med; 2017 Sep; 130(9):1112.e9-1112.e15. PubMed ID: 28344136
[TBL] [Abstract][Full Text] [Related]
17. ST2: a novel biomarker for heart failure.
Bhardwaj A; Januzzi JL
Expert Rev Mol Diagn; 2010 May; 10(4):459-64. PubMed ID: 20465500
[TBL] [Abstract][Full Text] [Related]
18. Dynamic observation of IL-33 and its receptors in HIV patients who received HAART.
He B; Zheng L; Zhou H; He Y; Chen Z; Xiao S; Wang H; Ling Y; Zheng Y
Cell Mol Biol (Noisy-le-grand); 2017 Mar; 63(3):73-77. PubMed ID: 28466817
[TBL] [Abstract][Full Text] [Related]
19. Soluble ST2--analytical considerations.
Mueller T; Jaffe AS
Am J Cardiol; 2015 Apr; 115(7 Suppl):8B-21B. PubMed ID: 25697919
[TBL] [Abstract][Full Text] [Related]
20. Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure.
Broch K; Andreassen AK; Ueland T; Michelsen AE; Stueflotten W; Aukrust P; Aakhus S; Gullestad L
Int J Cardiol; 2015 Jan; 179():378-84. PubMed ID: 25464491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
